Quotient Ltd (QTNT) Stock
QTNT is no longer traded. Quotient was delisted from the Nasdaq in March 2023.
Prices on this page are historical; the last trade was March 3, 2023 at $0.04.
Quotient stock price history
QTNT final trading statistics
- Final close
- $0.04
- Final trading day
- Mar 3, 2023
- Market cap at delisting
- $1.34M
- Shares outstanding
- 3.53M
- Final 52-week range
- $0.03 – $2.39
- Avg. volume (final 3 mo.)
- 1,645,238
- All-time high (split-adj.)
- $720.00 · Dec 2014
- All-time low (split-adj.)
- $0.04 · Feb 2023
- Return since IPO
- -100.0%
- Beta
- 2.19
- Book value / share
- -$53.62
- Price / book
- -0.00
Quotient annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $38.51M | -$125.1M | -$48.00 |
| FY2021 | $43.38M | -$108.5M | -$34.72 |
| FY2020 | $32.66M | -$102.8M | -$1.45 |
| FY2019 | $29.13M | -$105.4M | -$1.95 |
| FY2018 | $24.73M | -$82.3M | -$2.04 |
Last five fiscal years reported before the delisting; fiscal year ending March. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Quotient Ltd
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.
Quotient stock FAQ
What happened to Quotient stock?
Quotient stock was delisted from the Nasdaq. Its final close was $0.04 on March 3, 2023.
Is QTNT stock still trading?
No. QTNT was delisted from the Nasdaq in March 2023 and no longer trades on a U.S. exchange.
What was the last price of QTNT stock?
QTNT closed at $0.04 on its final trading day, March 3, 2023, for a market value of about $1.34M.
What were Quotient's revenue and earnings in its last full fiscal year?
Quotient reported revenue of $38.51M and net income of -$125.1M in fiscal 2022, its last full year as a public company.
When did Quotient go public?
Quotient Ltd stock began trading on April 25, 2014.